Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -97.93K | -92.27K | -52.64K | -24.50K | 0.00 |
EBITDA | -5.16M | -6.00M | -4.54M | -92.51K | -19.06K |
Net Income | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K |
Balance Sheet | |||||
Total Assets | 3.27M | 4.00M | 4.35M | 124.51K | 140.74K |
Cash, Cash Equivalents and Short-Term Investments | 1.11M | 2.38M | 3.49M | 95.91K | 140.74K |
Total Debt | 12.41M | 47.07K | 1.33M | 56.78K | 0.00 |
Total Liabilities | 15.11M | 2.67M | 1.64M | 136.77K | 60.49K |
Stockholders Equity | -23.88M | 1.33M | 2.71M | -12.26K | 80.25K |
Cash Flow | |||||
Free Cash Flow | -5.90M | -3.91M | -3.72M | -422.49K | -32.48K |
Operating Cash Flow | -4.92M | -3.64M | -3.56M | -46.23K | -32.48K |
Investing Cash Flow | -990.07K | -430.19K | -311.46K | -372.77K | 0.00 |
Financing Cash Flow | 4.58M | 2.96M | 1.27M | 30.00K | 0.00 |
Psyence Group Inc. announced a share consolidation, converting every fifteen old shares into one new share, effective April 23, 2025. This move, approved by shareholders and the board, aims to provide the company with greater flexibility for business development and growth, potentially impacting its market positioning and stakeholder interests.
Spark’s Take on TSE:PSYG Stock
According to Spark, TipRanks’ AI Analyst, TSE:PSYG is a Underperform.
Psyence Group faces significant financial challenges with ongoing losses and negative equity, which heavily impacts its overall score. While technical indicators show some positive momentum, the company’s negative P/E and lack of dividends reflect poor valuation. Recent corporate events offer a glimmer of hope for future growth, but the company’s financial instability and reliance on external funding remain key risks.
To see Spark’s full report on TSE:PSYG stock, click here.
Psyence Biomedical, an associate of Psyence Group, has strengthened its Scientific Advisory Board by appointing Dr. Dan J. Stein, a leader in psychopharmacology. This move supports their ongoing Phase IIb clinical trial of psilocybin for Adjustment Disorder in Palliative Care and plans to explore Alcohol Use Disorder treatment. This expansion aims to introduce new psilocybin-based therapeutics to meet unmet needs in mental health and addiction, potentially enhancing the company’s positioning in the psychedelic therapeutics industry.
Psyence Biomedical, an associate of Psyence Group, has appointed Dr. Albert P. Garcia-Romeu as the chair of its newly formed Scientific Advisory Board, enhancing its research capabilities in psilocybin-based treatments. Additionally, Psyence Group has settled a debt of C$120,000 by issuing shares, reflecting strategic financial management.